1-甲基-4-(2-羟乙基)-1,2,3,6-四氢吡啶 | 112654-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-甲基-4-(2-羟乙基)-1,2,3,6-四氢吡啶
• 英文名称: 1-methyl-4-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridine
• 英文别名: 1-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)ethanol
• CAS: 112654-70-3
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: ZCSSOYGMMFEJPI-UHFFFAOYSA-N

物化性质

• 沸点：
  224.6±20.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(2-羟乙基)-1,2,3,6-四氢吡啶 在 platinum(IV) oxide chromium(VI) oxide 、 氢气 作用下， 以 溶剂黄146 为溶剂， 21.0 ℃ 、310.27 kPa 条件下， 反应 18.0h， 生成 1-(1-甲基-4-哌啶基)-乙酮
  参考文献：
  名称：

  Synthesis, pharmacology, and molecular modeling studies of semirigid, nicotinic agonists

  摘要：

  Eight nicotinic agonists were synthesized, and their potencies were estimated by contracture of the frog rectus abdominis muscle. The most potent, 1-methyl-4-acetyl-1,2,3,6-tetrahydropyridine methiodide (3b), 50 times as potent as carbamylcholine, served as a template for the rest. Although all of the agonists could easily conform to the putative nicotinic pharmacophore, their potencies spanned a nearly 10,000-fold range. This pharmacophore, therefore, may be necessary but deficient. Computer-assisted molecular modeling studies helped to delineate additional factors that may contribute to potency. The factors are (1) the ground-state conformation, (2) superimposability of the hydrogen bond acceptor and the cationic head onto the template, (3) electrostatic potential at the cationic head and at the hydrogen bond acceptor site, and (4) the presence of a methyl group bonded to the carbon atom that bears the hydrogen bond acceptor. A new program, ARCHEM, was used to calculate and to visualize electrostatic potentials at the van der Waals surfaces of the agonists.

  DOI：

  10.1021/jm00398a010
• 作为产物：
  描述：

  4-乙酰吡啶 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 1-甲基-4-(2-羟乙基)-1,2,3,6-四氢吡啶
  参考文献：
  名称：

  简明，对映体合成的（3 S，4 R）-3-氨基-4-乙基哌啶作为非氟喹诺酮核的伴侣

  摘要：

  利用Overman可以从容易获得的（S）-（-）-α-甲基-4-吡啶甲醇6开始对映体特异性的八步合成（3 S，4 R）-3-氨基-4-乙基哌啶3手性烯丙基三氯乙酰亚胺酸酯13的重排是关键步骤。所得手性烯丙基胺15的非对映选择性氢化主要得到所需的反式取代的哌啶。哌啶的构象以及氨基官能团的定向性质与观察到的选择性有关。

  DOI：

  10.1016/s0040-4039(03)00421-0

文献信息

• [EN] IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY<br/>[FR] LIPIDES IONISABLES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：PREC NANOSYSTEMS INC

  公开号：WO2021000041A1

  公开（公告）日：2021-01-07

  The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery of nucleic acid and protein therapeutics for preparing and implementing T cell transfection, gene editing, cancer therapies, cancer prophylactics, and in the preparation of vaccines.

  本文件描述了核心公式（I）的化合物或其药用可接受盐，其中R1包括氨基团。这些化合物在核酸和蛋白治疗剂的制剂、体内和体外递送中特别有用，用于制备和实施T细胞转染、基因编辑、癌症治疗、癌症预防以及疫苗的制备。
• C-Alkylated spiro[benzofuran-3(2H),4′-1′-methyl-piperidine-7-ols] as potent opioids: A conformation-activity study
  作者：Ya-Ching Tsai、Jing-Ping Liou、Richard Liao、Chen-Yu Cheng、Pao-Luh Tao

  DOI：10.1016/s0960-894x(98)00318-7

  日期：1998.7

  Among a series of C-alkylated analogs of the weak mu opioid ligand spiro[benzofuran-3(2H),4'-1'-methylpiperidine-7-ol] (1), the 2-methyl, 2-ethyl, and cis 3'-methyl analogs, namely compounds (+/-)2, (+/-)-3, and (+/-)-4, showed much enhanced mu-affinities, with (+/-)-4 being almost as potent as (-)-morphine; while the trans 3'-methyl analog (+/-)-5 remained a weak mu-binder. Energy calculations and

  在弱μ阿片样物质配体螺[苯并呋喃-3（2H），4'-1'-甲基哌啶-7-ol]（1）的一系列C烷基化类似物中3'-甲基类似物，即化合物（+/-）2，（+/-）-3和（+/-）-4，显示出更高的mu亲和力，其中（+/-）-4几乎与如（-）-吗啡有效; 反式3'-甲基类似物（+/-）-5仍然是弱的mu-binder。能量计算和NMR数据表明，化合物2-4有利于苯基-轴向构象，而化合物1和5有利于苯基-赤道构象。
• Novel aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Hashihayata Takashi

  公开号：US20080305081A1

  公开（公告）日：2008-12-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R 3 and R 4 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, NR a R b , a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R 5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及由公式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2（可以相同也可以不同）分别是氢原子、低碳基、环烷基或类似物；R3和R4（可以相同也可以不同）分别是氢原子、低碳基、NRaRb、苯基、带苯基的低碳基、4-至7-成员的脂环杂环基、带4-至7-成员的脂环杂环基的低碳基、5-或6-成员的芳香杂环基、带5-或6-成员的芳香杂环基的低碳基或类似物；R5是氢原子、氰基、卤素原子或低碳基。
• NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2116543A1

  公开（公告）日：2009-11-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及一种由式 [I] 表示的化合物： 或其药学上可接受的盐或酯，其中R1和R2可以相同或不同，各自为氢原子、低级烷基、环烷基或类似物；R3 和 R4（可以相同或不同）各自是氢原子、低级烷基、NRaRb、苯基、被苯基取代的低级烷基、4-7 元脂肪杂环基、被 4-7 元脂肪杂环基取代的低级烷基、5-或 6 元芳香杂环基、被 5-6 元芳香杂环基取代的低级烷基或类似基团；R5 是氢原子、氰基、卤素原子或低级烷基。
• WATERS, JAMES A.;SPIVAK, CHARLES E.;HERMSMEIER, MARK;YADAV, JANARDAN S.;L+, J. MED. CHEM., 31,(1988) N 3, 545-554
  作者：WATERS, JAMES A.、SPIVAK, CHARLES E.、HERMSMEIER, MARK、YADAV, JANARDAN S.、L+

  DOI：——

  日期：——